Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

• Main Authors: Kongnakorn T (Author), Bharmal M (Author), Kearney M (Author), Phatak H (Author), Benedict A (Author), Bhanegaonkar A (Author), Galsky M (Author)
• Format: Book
• Published: Dove Medical Press, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Thitima Kongnakorn,1 Murtuza Bharmal,2 Mairead Kearney,3 Hemant Phatak,4 Agnes Benedict,5 Abhijeet Bhanegaonkar,4 Matthew Galsky6 1Evidence Synthesis, Modeling and Communication, Evidera, London, UK; 2Global Evidence and Value Development, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germa...